Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).

Abstract

AIMS/INTRODUCTION:

Tofogliflozin is a potent and highly selective sodium-glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3-year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiveness in routine clinical practice. The 3- and 12-month interim analysis showed tofogliflozin was well-tolerated, safe and clinically effective. Here, we report the results of the 24-month interim analysis.

MATERIALS AND METHODS:

This is a 3-year prospective, observational and multicenter post-marketing study (Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term).

RESULTS:

Of the 6,897 patients enrolled, 6,712 and 6,461 patients were analyzed for the safety and effectiveness of tofogliflozin, respectively. During the 24-month observation period, the incidence rates of adverse drug reactions (ADRs) and serious adverse drug reactions were 11.25 and 1.21%, respectively. As to adverse drug reactions of special interest, the incidence rates of hypoglycemia, polyuria/pollakiuria, volume depletion-related events, urinary tract infections and genital infection were 0.83, 1.28, 1.46, 1.18 and 1.62%, respectively. Renal disorders, and cardiovascular and cerebrovascular disorders occurred in 0.63 and 0.76% of the patients, respectively. Glycated hemoglobin A1c and bodyweight decreased significantly by -0.70% (P < 0.0001) and -2.95 kg (P < 0.0001), respectively, from baseline to week 104 (last observation carried forward).

CONCLUSIONS:

Significant safety concerns have not been observed, and clinical benefit including a long-term reduction in glycated hemoglobin A1c over a 104-week (24 months) observation period with weight loss was suggested in this 24-month interim analysis of the 3-year Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term in routine clinical practice.

• Authors: Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku
• Journal: Journal of diabetes investigation (J Diabetes Investig) Vol. 11 Issue 4 Pg. 906-916 (Jul 2020) ISSN: 2040-1124 [Electronic] Japan
• PMID: 32034997 (Publication Type: Journal Article, Multicenter Study, Observational Study)
• Copyright: © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Chemical References

• Benzhydryl Compounds
• Glucosides
• Glycated Hemoglobin A
• Sodium-Glucose Transporter 2 Inhibitors
• hemoglobin A1c protein, human
• 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol

Topics

• Aged
• Benzhydryl Compounds (therapeutic use)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Female
• Glucosides (therapeutic use)
• Glycated Hemoglobin (drug effects)
• Humans
• Japan
• Male
• Middle Aged
• Product Surveillance, Postmarketing
• Prospective Studies
• Sodium-Glucose Transporter 2 Inhibitors (therapeutic use)
• Treatment Outcome
• Weight Loss (drug effects)